CCHT's subsidiary has received approval for the clinical trial application for the domestic production of the injectable GenSci143 drug

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (hereinafter referred to as "JinSai Pharmaceutical"), has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, approving the clinical trial of GenSci143 injection in patients with advanced solid tumors.

GenSci143 is a Class 1 therapeutic biological product independently developed by JinSai Pharmaceutical, intended for the treatment of various advanced solid tumors such as prostate cancer and lung cancer. As a bispecific antibody-drug conjugate (BsADC) targeting B7-H3 and PSMA, GenSci143 has dual potential therapeutic effects of targeted chemotherapy and tumor immunotherapy, capable of overcoming tumor heterogeneity and resistance caused by reduced expression of a single target, thereby covering more patients and producing more durable anti-tumor efficacy

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.